PLATSAK, a potent antithrombotic and fibrinolytic protein, inhibits arterial and venous thrombosis in a baboon model

Thrombosis Research

Volumn 98, Issue 5, 2000, Pages 435-443

  Van Zyl, Walda B ^a   Pretorius, Gert H J ^a   Lamprecht, Sebastiaan ^a   Roodt, Jan P ^a   Kotzé, Harry F ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Antiplatelet; Antithrombin; Baboon model; Fibrinolytic; Hybrid molecule

Indexed keywords

STAPHYLOKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BABOON; CONTROLLED STUDY; DRUG EFFECT; FIBRINOLYSIS; HEMOSTASIS; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; VEIN THROMBOSIS;

ANIMALS; ANTITHROMBIN III; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; EVALUATION STUDIES; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; GAMMA CAMERAS; INDIUM RADIOISOTOPES; MALE; PAPIO; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; PLATELET ADHESIVENESS; PLATELET COUNT; RECOMBINANT FUSION PROTEINS; THROMBOSIS; TIME FACTORS;

EID: 0034212282     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00204-8     Document Type: Article

References (32)

1. Haskel E.J., Adams S.P., Feigen L.P., Saffitz J.E., Gorczynski R.J., Sobel B.E., Abendschein D.R. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation. 80:1989;1775-1782.
2. Bates E.R., McGillem M.J., Mickelson J.K., Pitt B., Mancini G.B.J. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation. 84:1991;2463-2469.
3. Willette R.N., Sauermelch C.F., Rycyna R., Sarkar S., Feuerstein G.Z., Nichols A.J., Ohlstein E.H. Antithrombotic effects of a platelet fibrinogen receptor antagonist in a canine model of carotid artery thrombosis. Stroke. 23:1992;703-711.
4. Hanson S.R., Pareti F.I., Ruggeri Z.M., Marzec U.M., Kunicki T.J., Montgomery R.R., Zimmerman T.S., Harker L.A. Effect of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and haemostasis in the baboon. J Clin Invest. 81:1988;149-158.
5. Cadroy Y., Houghten R.A., Hanson S.R. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. studies using a baboon model J Clin Invest. 84:1989;939-944.
6. Kotzé H.F., Badenhorst P.N., Lamprecht S., Meiring M., Van Wyk V., Nuyts K., Stassen J.M., Vermylen J., Deckmyn H. Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb Haemost. 74:1995;751-757.
7. Ruggeri Z.M., Houghton R.A., Russel S.R., Zimmerman T.S. Inhibition of platelet function with synthetic peptides designed to be high affinity antagonists of fibrinogen binding to platelets. Proc Natl Acad Sci USA. 83:1986;5708-5712.
8. Hanson S.R., Harker L.A. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-propyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci USA. 85:1988;3184-3188.
9. Kotzé H.F., Lamprecht S., Badenhorst P.N. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Blood. 85:1995;3158-3163.
10. Gruber A., Griffen J.H., Harker L.A., Hanson S.R. Inhibition of platelet dependent thrombus formation by human activated protein C in a primate model. Blood. 73:1989;639-642.
11. Haskel E.J., Torr S.R., Day K.C., Palmier M.O., Wun T.C., Sobel B.E., Abendschein D.R. Prevention of arterial reocclusion after thrombolysis with recombinant lipo-protein-associated coagulation inhibitor. Circulation. 84:1991;821-827.
12. Kotzé H.F., Lamprecht S., Badenhorst P.N., Roodt J.P., Van Wyk V. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb Haemost. 77:1997;1137-1142.
13. Knapp A., Degenhardt T., Dodt J. Hirudisins. J Biol Chem. 267:1992;24230-24234.
14. Church F.C., Phillips J.E., Woods J.L. Chimeric antithrombin peptide. characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptide J Biol Chem. 266:1991;11975-11979.
15. Leblond L., DiMaio J., Winocour P.D. Insertion of the Asp-Ser-Phe sequence in the P'position of hirutonin provides molecules having both antithrombin and disintegrin activity. Thromb Res. 93:1999;171-181.
16. Phaneuf M.D., Ozaki C.K., Johnstone M.T., Loza J.-P., Quist W.C., LoGerfo F.W. Covalent linkage of streptokinase to recombinant hirudin. a novel thrombolytic agent with antithrombotic properties Thromb Haemost. 71:1994;481-487.
17. Lijnen H.R., Wendt S., Schneider J., Janocha E., Van Hoef B., Collen D., Steffeus G.J. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. Eur J Biochem. 234:1995;350-357.
18. Yamada T., Shimada Y., Kikuchi M. Integrin-specific tissue-type plasminogen activator engineered by introduction of the Arg-Gly-Pro sequence. Biochem Biophys Res Commun. 228:1996;306-311.
19. Van Zyl W.B., Pretorius G.H.J., Hartmann M., Kotzé H.F. Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. Thromb Res. 88:1997;419-426.
20. Collen D., Lijnen H.R. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood. 84:1994;680-686.
21. Ruoslahti E., Pierschbacher M.D. New perspectives in cell adhesion. RGD and integrins Science. 238:1987;491-497.
22. Martin P.D., Robertson W., Turk D., Huber R., Bode W., Edwards B.F.P. The structure of residues 7-16 of the Aα-chain of human fibrinogen bound to bovine thrombin at 2.3Å resolution. J Biol Chem. 267:1992;7911-7920.
23. Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol. 19:1970;924-932.
24. Hanson S.R., Kotzé H.F., Savage B., Harker L.A. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis. 5:1985;595-603.
25. Hanson S.R., Harker L.A. Baboon models of acute arterial thrombosis. Thromb Haemost. 58:1987;801-805.
26. Cadroy Y., Horbett T.A., Hanson S.R. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo. J Lab Clin Med. 113:1989;436-448.
27. Johnson B.H., Hecht M.H. Recombinant proteins can be isolated from E. coli cells by repeated cycles of freezing and thawing. Biotechnology. 12:1994;1357-1360.
28. 2-receptor antagonist. Thromb Haemost. 70:1993;672-675.
29. Hanson S.R., Griffen J.H., Harker L.A., Kelly A.B., Esmon C.T., Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 92:1993;2003-2012.
30. Harker L.A. Strategies for inhibiting the effects of thrombin. Blood Coagul and Fibrinolysis. 5:1994;S47-S58.
31. Cerskus A.L., Ali M., Davies B.J., McDonald J.W.D. Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo. Thromb Res. 18:1980;389-397.
32. Meiring S.M., Lotter M.G., Badenhorst P.N., Bucha E., Novak G., Kotzé H.F. Sites of elimination and pharmacokinetics of recombinant I-131-lepirudin in baboons. J Pharm Sci. 88:1999;523-529.